Lab
Next Bio-Research Services, LLC.
Next Bio-Research Services, LLC. was paid $1.23M by Medicaid between Feb 2018 and Nov 2024, across 40 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 45% of everything it billed.
33Billing provider infoNEXT BIO-RESEARCH SERVICES, LLC.
CHESTER, VA 23831
CHESTER, VA 23831
33aNPI1760840482assigned 02/09/2016
33bProvider typeClinical Medical Laboratory
28Total paid$1.23M
24GClaims41,636
24DCodes billed40
24AFirst – last monthFeb 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#19 of 78
Median peer was paid$37K
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,644 | $118K | |
| 2019 | 3,178 | $200K | |
| 2020 | 4,908 | $260K | |
| 2021 | 8,705 | $294K | |
| 2022 | 16,013 | $316K | |
| 2023 | 5,739 | $38K | |
| 2024incomplete | 1,449 | $1K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 45% | 10,098 | 7,487 | $548K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 14% | 3,526 | 2,828 | $176K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 7.6% | 6,163 | 4,632 | $93K |
| 81226 | 5.2% | 184 | 182 | $64K | |
| 81225 | 3.3% | 183 | 181 | $41K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.2% | 280 | 267 | $27K |
| 81328 | 2.0% | 183 | 181 | $25K | |
| 81231 | 2.0% | 183 | 181 | $25K | |
| 81230 | 2.0% | 183 | 181 | $25K | |
| 81227 | 2.0% | 183 | 181 | $25K | |
| 87581 | 1.4% | 2,734 | 2,181 | $17K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 2,587 | 2,034 | $17K |
28 more codes
| 87541 | 1.3% | 2,572 | $16K | |
| 87486 | 1.3% | 2,735 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 2,053 | $15K |
| 81355 | 1.0% | 183 | $12K | |
| 87900 | <1% | 396 | $11K | |
| 81241 | <1% | 183 | $11K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 843 | $10K |
| 81350 | <1% | 65 | $9K | |
| 81240 | <1% | 183 | $9K | |
| 81291 | <1% | 183 | $9K | |
| 87653 | <1% | 602 | $5K | |
| 87481 | <1% | 602 | $5K | |
| 87503 | <1% | 1,823 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 412 | $4K |
| 87500 | <1% | 396 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 87 | $2K |
| 81401 | <1% | 183 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $513.28 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 110 | $344.76 |
| 80061 | Lipid panel | <1% | 187 | $260.41 |
| 80053 | Comprehensive metabolic panel | <1% | 221 | $181.62 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 199 | $122.80 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 170 | $117.60 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 182 | $77.41 |
| 84153 | <1% | 61 | $62.53 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 319 | $18.19 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 47 | $0.00 |
| 81479 | Unlisted molecular pathology procedure | 0% | 138 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREYNOLDS, THOMAS (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| 4Kidhelp INC | Canton, OH | $766K |
| Chattanooga Vision Center, PLC | Chattanooga, TN | $2K |
| Next Bio-Research Services, LLC. | Rockville, MD | $100.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.